Essex Bio-Technology Limited (HKG:1061)

Market Cap	2.49B
Revenue (ttm)	1.67B
Net Income (ttm)	307.22M
Shares Out	567.01M
EPS (ttm)	0.53
PE Ratio	8.27
Forward PE	7.72
Dividend	0.12 (2.62%)
Ex-Dividend Date	May 23, 2025

Volume	549,000
Average Volume	4,079,910
Open	4.390
Previous Close	4.400
Day's Range	4.350 - 4.600
52-Week Range	2.150 - 5.150
Beta	-0.11
RSI	59.35
Earnings Date	May 9, 2025

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in the People’s Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levoflox...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 1,450
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1061

Financial Performance

In 2024, Essex Bio-Technology's revenue was 1.67 billion, a decrease of -3.87% compared to the previous year's 1.74 billion. Earnings were 307.22 million, an increase of 11.61%.